01 / INTEGRATE
Connect data modalities
Harmonize genomics, transcriptomics, proteomics, metabolomics, imaging, and longitudinal clinical measures into a coherent analytic framework.
Consulting · Neurodegeneration + Metabolic Disease
Turn complex data into clinical insight.
NeuroHub Analytics LLC integrates high-throughput molecular, clinical, and imaging data to build better diagnostic and prognostic models for neurodegenerative diseases, with particular expertise in the links between neurodegeneration and metabolic disease.
35+peer-reviewed publications
Multi-modalmolecular, clinical & imaging analytics
AD · PD · ALS · MetabolicNeurodegenerative diseases, diabetes & related disorders
What we solve
From raw signal to a defensible model.
Good biomarker work is more than a statistical association. We connect biological context, rigorous analysis, and clinical relevance so that every result can survive the next question.
02 / DISCOVER
Find meaningful signals
Use reproducible statistical and network-based methods to identify biomarkers, molecular pathways, patient subtypes, therapeutic hypotheses, and links between metabolic dysfunction and neurodegeneration.
03 / TRANSLATE
Build useful models
Develop and validate diagnostic and prognostic models with attention to effect size, generalizability, clinical interpretation, and next-step validation.
Replication and validation
Tested across independent clinical cohorts.
Dr. Santiago’s biomarker work extends from discovery through replication and validation, drawing on five major independent Parkinson’s disease research cohorts and programs.
PROBEPrognostic and Diagnostic Biomarkers for Parkinson’s Disease
HBSHarvard Biomarker Study
PPMIParkinson’s Precision Medicine Initiative
PARSParkinson’s Associated Risk Syndrome Study
PDBPParkinson’s Disease Biomarkers Program
Selected research
A publication record grounded in translational science.
Research across blood-based biomarkers, molecular networks, metabolic comorbidity, lifestyle, and clinically meaningful outcomes in Parkinson’s disease, Alzheimer’s disease, ALS, and related disorders.
PNASResearch article
Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease
Santiago JA · Potashkin JA
Trends in Molecular MedicineCover article
GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach
Santiago JA · Gutierrez-Silva JC · Hsu WC · et al.
Movement DisordersResearch article
Specific splice variants are associated with Parkinson’s disease
Santiago JA · Scherzer CR · Potashkin JA
Who we support
Scientific depth, shaped to the decision.
Flexible collaboration for teams that need a senior scientific perspective, additional analytic capacity, or an independent assessment of a biomarker strategy.
Biotech & pharma
Biomarker strategy, target prioritization, patient stratification, and evidence generation for neurodegenerative disease programs.
Academic investigators
Study design, high-dimensional analysis, replication planning, figures, manuscripts, and grant-ready analytic frameworks.
Research organizations
Independent analysis of complex cohort data, multimodal integration, and reproducible delivery for collaborative programs.
Contact us
Let’s discuss your research.
For consulting inquiries, collaborations, or questions about a potential project, contact Dr. Jose A. Santiago directly.
jose.santiago@neurohubanalytics.com